Femasys FEMY 深 沪
等待开盘 08-19 09:30:00 美东时间
2.20
+0.040
+1.85%
华盛通- 最 高2.2489
- 今 开2.16
- 成交量 14.68万股
- 最 低 2.0644
- 昨 收 2.16
- 总市值 1842.51万
- 52周最高 22.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.0223
- 委 比 69.51%
- 总股本 837.50万
- 历史最高 275.00
- 量 比 0.51
- 振 幅 8.54%
- 历史最低 2.0644
- 每 手 1
- 风险率 4.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 66.25 percent increase over losses of $(3.20) per share from the same period last year. The company reported quarterly sales of $756.716 thousand which...
08-15 04:15
Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10
Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $30 to $10.
08-15 04:15
Femasys completes $30 million private placement financing
The latest announcement is out from Femasys ( ($FEMY) ). On August 7, 2026, Fem...
08-12 05:22
Femasys Announces $30M Private Placement Led By New Investors And Members Of Management
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purc...
08-07 21:32
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Inc. announced a $30 million private placement with accredited investors, led by Nantahala Capital, to strengthen its balance sheet and advance its fertility and non-surgical birth control solutions. The offering includes shares and warrants, with potential additional proceeds of up to $60 million if all warrants are exercised. The company aims to expand access to its innovative products and improve healthcare outcomes for women worldwide...
08-07 13:25
Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for
05-13 21:05
Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment
The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and
05-05 21:15
Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today a strategic
04-16 21:03
